เอกสารอ้างอิง

1.	Leone  B, Romero A, Rabinovich M, et  al. Stage IV breast cancer: clinical  course  and   survival  of  patients  with   osseous  versus extraosseous   metastases  at  initial  diagnosis.  Am  J  Clin  Oncol 1988;11:618.
2.	Olson M,  Chernik N, Posner J. Infiltration  of the leptomeninges by  systemic cancer:  a  clinical and  pathologic  study. Arch  Neurol 1974;30:1222.
3.	Howell A,  Defriend D, Robertson J, et al. Response to a specific antioestrogen  (ICI  182780)  in  tamoxifen-resistant  breast  cancer.  Lancet 1995;345:29.
4.	Tondini C, Hayes  D, Gelman R,  et al. Comparison  of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 1988;48:4107.
5.	Brooks S, Saunders  D, Singhakowinta A, et al. Relation  of tumor content  of estrogen  and  progesterone  receptors  with  response  of patients to endocrine therapy. Cancer 1980;46:2775.
6.	Dao T,  Nemoto T.  Steroid receptors  and response  to endocrine ablations  in  women with  metastatic  cancer  of  the breast.  Cancer 1980;46:2779.
7.	Bezwoda W, Esser  J, Dansey R, et al.  The value of estrogen  and progesterone receptor determinations in advanced breast cancer. Cancer 1991;68:867.
8.	Allegra J,  Lippman  M,  Thompson E,  et  al. Estrogen  receptor status:  an important  variable in  predicting  response to  endocrine therapy in metastatic breast cancer. Eur J Cancer 1980;16:323.
9.	Falkson  G, Gelman  R, Falkson C,  et al. Factors  predicting for response, time  to  treatment  failure, and  survival  in  women  with metastatic breast  cancer treated  with DAVTH:  a prospective  Eastern Cooperative Oncology Group study. J Clin Oncol 1991;9:2153.
10.	Santen  R, Worgul  T,  Samojlik  E, et  al.  A randomized  trial comparing   surgical   adrenalectomy   with   aminoglutethimide   plus hydrocortisone  in women  with advanced  breast cancer.  N Engl  J Med 1981;305:545.
11.	Muss H, White D, Richard S, et al. Adriamycin versus methotrexate in  five-drug combination chemotherapy  for advanced breast  cancer: a randomized trial. Cancer 1978;42:2141.
12.	Ibrahim N,  Buzdar A. Aromatase inhibitors: current  status. Am J Clin Oncol 1995;18:407.
13.	Wiebe V,  Osborne C,  Fuqua  S, et  al. Tamoxifen  resistance in breast cancer. CRC Crit Rev Oncol Hematol 1993;14:173.
14.	Hudis C,  Seidman A, Crown J,  et al. Phase II  and pharmacologic study  of  docetaxel  as initial  chemotherapy  for  metastatic breast cancer. J Clin Oncol 1996;14:58.
15.	Seidman  A, Hudis  C, Norton  L. Memorial  Sloan-Kettering Cancer Center experience with paclitaxel  in the treatment of  breast cancer: from advanced disease to adjuvant therapy. Semin Oncol 1995;22:108.
16.	Holmes F. Update: the M.D. Anderson Cancer Center experience with paclitaxel   in  the  management  of  breast  carcinoma.  Semin  Oncol 1995;22:9.
17.	A'Hern R, Smith I, Ebbs S. Chemotherapy and survival in advanced breast cancer: the  inclusion of doxorubicin in Cooper  type regimens. Br J Cancer 1993;67:801.
18.	Buzdar A,  Marcus C, Smith T,  et al. Early and  delayed clinical cardiotoxicity of doxorubicin. Cancer 1985;55:2761.
19.	Speyer J, Green M, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in  women with breast cancer. J Clin Oncol 1992;10:117.
20.	Seidman A,  Hochhauser D,  Gollub M, et  al. 96  hour paclitaxel infusion after  progression during short  taxane exposure: a  phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996 (in press).
21.	Dombernowsky  P,  Gehl  J,  Boesgaard M,  et  al.  Treatment  of metastatic  breast cancer with paclitaxel and doxorubicin. Semin Oncol 1995;22(Suppl 15):13.
22.	Holmes  F. Combination  chemotherapy with  Taxol (paclitaxel)  in metastatic breast cancer. Ann Oncol 1994;5:23.
23.	Muss H, Case L, Richards F, et al.  Interrupted versus continuous chemotherapy  in patients  with metastatic  breast cancer. N  Engl Med 1991;325:1342.
24.	Crown J,  Raptis G, Hamilton N, et al.  High-dose chemotherapy of breast  cancer: current  status and  developmental  strategies. Eur  J Cancer 1995;31A:809.

---